Results 61 to 70 of about 6,245 (194)

AI‐Enabled Precision Dosing in Pediatrics: Enhancing Model‐Informed Decision Making

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Ensuring safe and effective pharmacotherapy for children remains a central challenge in clinical pharmacology, yet rapid advances in AI have not translated into clinical practice. This Perspective highlights how AI‐enabled approaches can enhance model‐informed decision making for precision dosing.
Kei Irie, Tomoyuki Mizuno
wiley   +1 more source

Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke   +12 more
wiley   +1 more source

Multiscale classification of heart failure phenotypes by unsupervised clustering of unstructured electronic medical record data

open access: yesScientific Reports, 2020
As a leading cause of death and morbidity, heart failure (HF) is responsible for a large portion of healthcare and disability costs worldwide. Current approaches to define specific HF subpopulations may fail to account for the diversity of etiologies ...
Tasha Nagamine   +7 more
doaj   +1 more source

Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 435-447, March 2025.
Abstract Intranasal diamorphine (IND), approved for managing breakthrough pain in the UK, has been identified as an acceptable alternative offering effective, expedient, and less traumatic analgesia for children. However, the current dose regimen in pediatric populations relies on clinical expertise while the pharmacokinetics properties are poorly ...
Lianjin Cai   +6 more
wiley   +1 more source

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet   +8 more
wiley   +1 more source

Opinion: The Pharmacometrics of Infectious Disease

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2013
The application of pharmacometric principles to the treatment of infectious diseases must address important biological issues across the diversity of pathogenic organisms. Recent applications of pharmacometric tools in this therapeutic area have had important translational impact not only in drug development but on real‐world clinical practice.
Davies, G R, Hope, W, Khoo, S
openaire   +2 more sources

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux   +6 more
wiley   +1 more source

Modeling of Disease Progression of Type 2 Diabetes Using Real‐World Data: Quantifying Competing Risks of Morbidity and Mortality

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 606-615, March 2025.
ABSTRACT Type 2 diabetes (T2D) is a progressive metabolic disorder that could be an underlying cause of long‐term complications that increase mortality. The assessment of the probability of such events could be essential for mortality risk management. This work aimed to establish a framework for risk predictions of macrovascular complications (MVC) and
Hanna Kunina   +2 more
wiley   +1 more source

Optimizing Perioperative Management of Haemophilia B With rFIX‐FP: Pharmacokinetic Validation of the Hemoptidose Tool

open access: yesHaemophilia, EarlyView.
Abstract Background Surgical management of haemophilia B requires precise factor IX replacement to ensure adequate haemostasis while optimizing factor consumption. Extended half‐life rFIX‐FP simplifies perioperative management but exhibits substantial pharmacokinetic variability.
Xavier Delavenne   +10 more
wiley   +1 more source

Pharmacokinetics of Moxidectin in Bare‐Nosed Wombats (Vombatus ursinus) After Intravenous, Sub‐Cutaneous and Transdermal Administration

open access: yesJournal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT The anti‐parasitic drug moxidectin is a frontline treatment for sarcoptic mange in bare‐nosed wombats (Vombatus ursinus), a disease causing significant animal welfare issues and instances of local population declines. Despite widespread usage, knowledge of species‐specific pharmacokinetics of moxidectin in bare‐nosed wombats is still limited ...
E. K. Stott   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy